Clinical Trials

MERIDIAN

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

Eligible tumor type: Head and Neck Cancer

Sponsor: In-house

PI: Dr. Lillian Siu

NCT#: NCT05414032

For more information visit https://clinicaltrials.gov/ct2/show/NCT05414032

TBI-2001

Phase I/Ib Study of TBI-2001 for Patients with Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Eligible tumor type: Hematological Malignancies

Sponsor: In-house

PI: Dr. Marcus Butler

NCT#: NCT05963217

For more information visit https://clinicaltrials.gov/ct2/show/NCT05963217

ADP-0055-001

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors

Eligible tumor type: Esophageal Cancer, Esophagogastric Junction Disorder, Gastric Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, Uroethelial Cancer

PI: Dr. Marcus Butler

NCT#: NCT04044859

For more information visit https://clinicaltrials.gov/ct2/show/NCT04044859

ADP-0044-002

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS)

Eligible tumor type: Synovial Sarcoma, Myxoid/Round Cell Liposarcoma (MRCLS)

PI: Dr. Albiruni Razak

NCT#: NCT04044768

For more information visit https://clinicaltrials.gov/ct2/show/NCT04044768

IOV-COM-202

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

Eligible tumor type: Melanoma, Head and Neck Cancer, Non-Small Cell Lung Cancer (NSCLC)

PI: Dr. Adrian Sacher

NCT#: NCT03645928

For more information visit https://clinicaltrials.gov/ct2/show/NCT03645928

IOV-LUN-202

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

Eligible tumor type: Non-Small Cell Lung Cancer (NSCLC)

PI: Dr. Adrian Sacher

NCT#: NCT04614103

For more information visit https://clinicaltrials.gov/ct2/show/NCT04614103

INSPECT-IO

Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients

Eligible tumor type: Solid Tumour

Sponsor: In-house

PI: Dr. Anna Spreafico

NCT#: NCT04107311

For more information visit https://clinicaltrials.gov/ct2/show/NCT04107311

LANDMARC

PLandscape Mapping of Epitopes and T Cell Receptors for Selected Cancers

Eligible tumor type: Hepatocellular Carcinoma (HCC), Epstein-Barr Virus (EBV)- and Human Papillomavirus (HPV)- related cancers

Sponsor: In-house

PI: Dr. Kathy Han

TBio-4101-001

A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)

Eligible tumor types: Breast Cancer, Colorectal Cancer, Metastatic Melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and Neck Cancer

PI: Dr. Marcus Butler

NCT#: NCT05576077

For more information visit https://clinicaltrials.gov/ct2/show/NCT05576077

ADP-0055-003

A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers

Eligible tumor types: Ovarian Cancer

PI: Dr. Neesha Dhani

NCT#: NCT05601752

For more information visit https://clinicaltrials.gov/ct2/show/NCT05601752

PANTHEON-IO

Phase 1 trial of Pantothenic acid in patient with metastatic or unresectable melanoma on Immunotherapy

Eligible tumor types: Metastatic Melanoma

Sponsor: In-house

PI: Dr. Samuel Saibil

TAC01-CLDN18.2-04

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors

Eligible tumor types: Solid Cancer

Sponsor: In-house

PI: Dr. Samuel Saibil

NCT#: NCT05862324

For more information visit https://clinicaltrials.gov/ct2/show/NCT05862324

ACTIVATE

Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study

Eligible tumor types: Ovarian cancer, Metastatic Melanoma

Sponsor: In-house

PI: Dr. Marcus Butler

NCT#: TBD

1301-02

Phase 1b Study of NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes in Patients with Solid Tumors

Eligible tumor types:Solid Cancer

Sponsor: In-house (in collaboration with Takara Bio Inc)

PI: Dr Marcus Butler

NCT#: NCT02869217

For more information visit https://clinicaltrials.gov/ct2/show/NCT02869217

INSPIRE

INvestigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

Eligible tumor types: metastatic melanoma, triple negative breast cancer, squamous cell cancer of the head and neck, ovarian cancer, solid cancers

Sponsor: In-house

PI: Dr. Lillian Siu

NCT#: NCT02644369

For more information visit https://clinicaltrials.gov/ct2/show/NCT02644369

METADUR

An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors

Eligible tumor types: Breast Cancer, Colorectal Cancer, Ovarian Cancer

Sponsor: In-house

PI: Dr. Lillian Siu

NCT#: TBD

TILs-003-Meso

Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)

Eligible tumor types: malignant pleural mesothelioma

Sponsor: In-house

PI: Dr. Marcus Butler

NCT#: NCT02414945

For more information visit https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1

TILs-002-MEL

Phase II Study Evaluating the Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma

Eligible tumor type: Metastatic Melanoma

Sponsor: In-house

PI: Dr. Marcus Butler

NCT#: NCT01883323

For more information visit https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1

TILs-001-DC

A Phase I Study Evaluating the Feasibility and Safety of Infusion of Re-StimulatedAutologous Tumor-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients with Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Eligible tumor type: Ovarian Cancer

Sponsor: In-house

PI: Dr. Marcus Butler

NCT#: NCT01883297

For more information visit https://clinicaltrials.gov/ct2/show/NCT01883297

MET4-IO

Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy

Eligible tumor types: Solid Cancer

Sponsor: In-house

PI: Dr. Anna Spreafico

NCT#: NCT03686202

For more information visit https://clinicaltrials.gov/ct2/show/NCT03686202

IMCnyeso-101

A phase I/II study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific soluble T-cell receptor and anti-CD3 bispecific molecule, in HLA-A*0201 positive patients with advanced NY-ESO-1 and/or LAGE - 1A positive cancer

Eligible tumor types: Solid Cancer

PI: Dr. Marcus Butler

NCT#: NCT03515551

For more information visit https://clinicaltrials.gov/ct2/show/NCT03515551

GSK208750

Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies

Eligible tumor types: Solid Cancer

PI: Dr. Adrian Sacher

NCT#: NCT03391778

For more information visit https://clinicaltrials.gov/ct2/show/NCT03391778

SQZ-PBMC-HPV-101

A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Eligible tumor types: Solid Cancer

PI: Dr. Neesha Dhani

NCT#: NCT04084951

For more information visit https://clinicaltrials.gov/ct2/show/NCT04084951

CRSP-ONC-003

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation

Eligible tumor types: Renal Cell Carcinoma

PI: Dr. Adrian Sacher

NCT#: NCT04438083

For more information visit https://clinicaltrials.gov/ct2/show/NCT04438083

TCR2-18-01

A Phase 1/2 Single Arm Open-Label Clinical Trial of Tc-210 T Cells In Patients with Advanced Mesothelin-Expressing Cancer

Eligible tumor types: Solid Cancer

PI: Dr. Marcus Butler

NCT#: NCT03907852

For more information visit https://clinicaltrials.gov/ct2/show/NCT03907852